At today's price, UnitedHealth's stock is pricing in about 5.6% annual free-cash-flow growth for the next ten years. Before its 2025 crisis, the company's actual free-cash-flow growth ran 13.6% a year — but including the crisis, the trailing five-year rate was actually -5.2% a year.
At its current price, UNH implies ~5.6% annual free-cash-flow growth for the next 10 years, discounted at 10%.
Pre-crisis (2021–2023), UnitedHealth's actual FCF growth averaged 13.6% a year. Including the 2025 crisis, the trailing five-year (2021–2025) rate was -5.2% a year.
Required growth vs. historical growth
Required growth from the reverse DCF below. FCF = operating cash flow − capital expenditures. Pre-crisis CAGR: 2021 FCF ($19,889M) to 2023 peak ($25,682M). Five-year CAGR: 2021 FCF ($19,889M) to 2025 ($16,075M). Revenue CAGR: 2021 ($287,597M) to 2025 ($447,567M). Source: 10-K FY2025, p.27, p.44; 10-K FY2021, p.27, p.43.
Sensitivity: what if the discount rate moves?
| WACC | Required growth |
|---|---|
| 8% | 1.4% |
| 9% | 3.6% |
| 10% (base case) | 5.6% |
| 12% | 9.2% |
UnitedHealth is classified as a large, stable company (market cap over $350B), giving it a base-case WACC of 10%. At a lower discount rate (8%), required growth falls to just 1.4%; at a higher one (12%), it climbs to 9.2% — nearly double the base case.
What would move this number
- Switching the FCF base from trailing-twelve-month ($23,617M) to the FY2025 audited figure alone ($16,075M) raises the required growth rate sharply, from 5.6% to 10.8% — because 2025 was the crisis trough, using it as the starting point demands a much steeper future climb.
- Using a three-year (2023–2025) average FCF ($20,821M) instead puts the required growth rate at 7.3%, in between.
- Lowering the terminal growth rate from 2.5% to 2.0% raises the required growth rate slightly, since a smaller terminal value has to be made up for during the explicit growth period.
Show your work
Inputs, sources, model assumptions, and the calculation
- Share price$395.62 — stockanalysis.com, Aug 17, 2026 close
- Diluted shares outstanding906M — 10-Q Q2 FY2026, income statement (three months ended Jun 30, 2026)
- Market cap$358,432M — price × diluted shares (calculated)
- Net debt$44,743M — 10-Q Q2 FY2026 balance sheet: total debt ($73,328M) minus cash and equivalents ($28,585M), as of Jun 30, 2026
- Trailing-twelve-month FCF$23,617M — calculated: FY2025 FCF ($16,075M) minus H1 2025 FCF ($10,860M) plus H1 2026 FCF ($18,402M), from the 10-Q Q2 FY2026 cash flow statement
- Discount rate (WACC)10% base case (8% / 12% tested) — large stable-company default
- Terminal growth rate2.5% — long-run GDP-level assumption
Normalization check: trailing-twelve-month FCF ($23,617M) is +13.4% above the three-year (2023–2025) average ($20,821M) — within the ±40% threshold, so used as-is without adjustment. FY2025 alone, by contrast, sits -22.8% below that same three-year average, confirming 2025 was a genuine trough year.
Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's enterprise value (market cap + net debt).
The fine print
- Change the discount rate, the FCF base, the projection window, or the terminal growth rate, and the answer moves significantly — see the sensitivity table above.
- A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
- Whether 5.6% growth is realistic depends on whether the 2025 crisis (guidance collapse, CEO change, DOJ investigation) is genuinely over — this math alone can't answer that.
- Any investment decision, and its outcome, is your own responsibility.
Frequently asked questions
What growth rate does UNH's stock price assume?
At today's price, UnitedHealth's stock is pricing in about 5.6% annual free-cash-flow growth for the next ten years.
How does that compare to UnitedHealth's actual growth?
Before its 2025 crisis, UnitedHealth's actual free-cash-flow growth ran 13.6% a year — well above what the price now requires — but including the crisis, the trailing five-year rate was actually -5.2% a year.
What share price was used for this analysis?
This analysis used $395.62, as of Aug 17, 2026.